ADVANCED HUMAN IMAGING LTD (AHI)

name changed to Advanced Health Intelligence Ltd

The suspension of trading in the securities of Advanced Human Imaging Ltd will be lifted from the commencement of trading on Friday, 14 October 2022 following lodgement of its Audited Financial Statement for the period ended 30 June 2022.

The company lodges its annual report. In the preliminary final report and Appendix 4E for the financial year ended 30 June 2022, released on 1 September 2022, the company reported an unaudited net loss after tax of $20,572,729. During the course of the audit, it was determined that the company had incorrectly accounted for some of its non-cash share based payments during the course of the year, which when corrected increased the company's audited net loss after tax from $20,572,729 to $22,641,925 for the year ended 30 June 2022.

The Company will not be lodging its 2022 financial statements until 12 October 2022. This further delay has been necessary to ensure that all new and existing audit requirements have been completed and will form the basis for the required reporting in the United States of America, following the Company's successful listing on NASDAQ.

The securities of the company will be suspended from Official Quotation in accordance with Listing Rule 17.5 from the commencement of trading today, 3 October 2022, following their failure to lodge the relevant periodic report by the due date.

There will be a delay in the lodgement of the Company's Financial Statements for the year ended 30 June 2022. The delay is to allow the Company to complete all the requirements of its newly appointed Auditor, PKF Brisbane Audit.

The suspension of trading in the securities of Advanced Human Imaging Ltd will be lifted from the commencement of trading on Friday, 2 September 2022, following the release by AHI of an announcement regarding a material acquisition and a response to an ASX Price Query.

The company has entered into a definitive arrangement agreement with wellteq Digital Health Inc. whereby AHI will acquire all of the outstanding shares of wellteq in an all-share acquisition. wellteq shareholders will receive one (1) ordinary share of AHI for every six (6) wellteq common shares held (or 0.1667 AHI Shares for every 1 wellteq Share). AHI will issue a total of approximately 17,811,508 AHI shares in total consideration for 100% of wellteq's shares. Following completion of the Transaction, wellteq shareholders in aggregate will hold approximately 9.573% of AHI's issued capital.

The company issues a response to ASX Price Query.

The securities of Advanced Human Imaging will be suspended from quotation immediately under Listing Rule 17.2, at the request of AHI, pending the release of an announcement regarding a material acquisition and a response to an ASX Price Query.

The suspension of trading in the securities of Advanced Human Imaging Ltd will to be lifted immediately following the release by AHI of an announcement regarding the Company's recently completed Nasdaq capital raising.

The company issued a notice of proposed issue of securities.

The company's convertible note subscription agreements with Asia Cornerstone Asset Management ) and iConcept Global Growth Fund have been settled by mutual agreement. The Company has agreed to issue 2,271,834 fully paid ordinary shares represented by American Depository Shares to ACAM and 738,576 ADSs to iCGGF in full and final settlement of all claims under or in connection with the Agreements.

The company's previously announced U.S. initial public offering of 1,000,000 units at a price to the public of US$10.50 per unit has closed. t. Each unit issued in the offering consisted of two American Depositary Shares and one warrant to purchase one ADS. Each ADS offered represented 7 ordinary shares of AHI. The warrants were exercisable immediately, expire three years from the date of issuance and have an exercise price of US$5.52 per ADS. The ADSs and warrants were immediately separable and were issued separately. , AHI granted to Maxim Group LLC a 45-day option to purchase up to an additional 300,000 ADSs and/or up to an additional 150,000 warrants to purchase up to 150,000 ADSs, at the public offering price less underwriting discounts, of which Maxim Group LLC has partially exercised its option to purchase such 150,000 warrants to purchase up to 150,000 ADSs.

The securities of Advanced Human Imaging Ltd will be suspended from quotation immediately under Listing Rule 17.2, at the request of AHI, pending the release of an announcement in connection with the Company's recently completed Nasdaq capital raising.

The suspension of trading in the securities of Advanced Human Imaging Ltd will be lifted from the commencement of trading on Monday, 19 April 2021, following the receipt of a response to an ASX Price and Volume Query.

The company releases a response to ASX price and volume query.

AHI has concluded all required due diligence required under the Binding term sheet. AHI has now executed all formal agreements with Triage Technologies. AHI to implement Triage's Artificial Intelligence "health assistant" technology within the CompleteScan SaaS offering. Triage AI technology platform can currently identify 588 skin conditions in 133 major categories via smartphone and is currently available in 200 countries around the world. The Triage AI platform has been used over 600,000 times since launch in late 2019. Advanced Human Imaging will also take a strategic equity stake in Triage.

Physimax has developed Advanced Musculoskeletal Assessment Artificial Intelligence. Musculoskeletal conditions affect 1.71 billion people worldwide. Musculoskeletal disorders such as lower back pain cause the highest burden on healthcare systems with a prevalence of 568 million people worldwide. Musculoskeletal conditions are the leading contributor to disability worldwide, causing disability in 160 countries. Musculoskeletal conditions significantly limit mobility and dexterity, leading to early retirement from work, lower levels of well-being and reduced ability to participate in society. Due to population increases and ageing, the number of people with musculoskeletal conditions is rapidly increasing. The disability associated with musculoskeletal conditions has been increasing and is projected to continue to increase in the next decade. $16 billion lost annually from Australian GDP due to Musculoskeletal conditions. Physimax is chosen by clinicians, elite sports teams, and the US Military.

The suspension of the company's securities is expected to last until the earlier of the company finalising the response and announcement in relation to the material potential acquisition or commencement of trade on 20 April 2021.

The suspension of the company's securities is expected to last until the earlier of the company finalising the response and announcement regarding the company's response to ASX's price and volume query letter and an announcement in relation to a material potential acquisition, or commencement of trade on 13 April 2021.

The securities of Advanced Human Imaging Ltd will be suspended from quotation immediately under Listing Rule 17.2, at the request of AHI, pending the Company's response to ASX's price query letter dated 30 March 2021.

name changed from MyFiziq Limited